Vaxcyte (PCVX) Net Cash Flow (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Net Cash Flow data on file, last reported at $87.5 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 307.47% year-over-year to $87.5 million in Q1 2026; TTM through Mar 2026 was -$86.5 million, a 66.74% increase from a year earlier, with the FY2025 full-year figure at -$216.2 million, down 2109.6% from the prior year.
• Net Cash Flow for Q1 2026 stood at $87.5 million, up from -$107.3 million in the prior quarter.
• Over the last five years, Net Cash Flow for PCVX reached as high as $555.5 million in Q4 2022 and fell as low as -$663.7 million in Q4 2024.
• Historically, Net Cash Flow has averaged $11.6 million across 5 years, with a median of $13.3 million in 2023.
• Across the five-year window, Net Cash Flow slumped 441.57% in 2023 and jumped 3945.4% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $555.5 million in 2022, then tumbled by 125.2% to -$140.0 million in 2023, then slumped by 374.04% to -$663.7 million in 2024, then surged by 83.83% to -$107.3 million in 2025, then soared by 181.59% to $87.5 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $87.5 million in Q1 2026, -$107.3 million in Q4 2025, and -$25.8 million in Q3 2025.